Emergent BioSolutions | EBS - Marktkapitalisierung





Marktkapitalisierung Veränderung Datum
Acadia Pharmaceuticals USD 4.53B 199M 2026-08
Akebia Therapeutics USD 427M 297M 2025-12
ALKERMES USD 7.93B 806M 2026-08
Alnylam Pharmaceuticals USD 40.19B 3.96B 2026-06
Amarin USD 290M 51M 2025-12
ANI Pharmaceuticals USD 1.59B 293M 2026-08
BioMarin Pharmaceutical USD 11.71B 651M 2026-08
Coherus Biosciences USD 172M 19M 2025-12
Emergent BioSolutions USD 125M 51M 2023-12
Exelixis USD 15.27B 1.73B 2026-08
Glaxosmithkline GBP 109.29B 9.36B 2026-03
Heron Therapeutics USD 238M 7M 2025-12
Ionis Pharmaceuticals USD 13.1B 642M 2026-06
Lexicon Pharmaceuticals USD 418M 73M 2025-12
Lonza CHF 39.68B 980.61M 2025-06
Merck USD 324.18B 6.81B 2026-08
Nektar Therapeutics USD 12.98B 10.86B 2026-08
Neurocrine Biosciences USD 16.95B 3.7B 2026-06
Pacira USD 1.28B 286M 2026-08
Pfizer USD 153.17B 14.73B 2026-08
Sanofi EUR 91.15B 9.12B 2026-06
Sarepta Therapeutics USD 1.5B 402M 2026-08
United Therapeutics USD 24.42B 1.42B 2026-08
Vanda Pharmaceuticals USD 279M 6M 2024-12